Mar 27 |
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
|
Mar 22 |
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years
|
Mar 20 |
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
|
Mar 19 |
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
|
Mar 14 |
Citi starts Catalyst at buy, cites rare disease drug portfolio
|
Mar 13 |
Catalyst announces US launch of Duchenne drug Agamree
|
Mar 13 |
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
|
Mar 7 |
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
|
Mar 5 |
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
|
Feb 29 |
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript
|